Merck Announces First-Quarter 2012 Financial Results
- 2012 First-Quarter Non-GAAP EPS Increased Eight Percent Over Prior Year to $0.99, Excluding Certain Items; GAAP EPS of $0.56
- Worldwide Sales Grew One Percent to $11.7 Billion Driven by Growth of Three Percent in Pharmaceuticals (Six Percent, Excluding the Impact of the J&J Arbitration Settlement), Eight Percent in Animal Health and Seven Percent in Consumer Care
- Strong Growth Across All Major Businesses Partially Offset by Reductions in Alliance Revenue and Third-Party Manufacturing Sales
- Double-Digit Global Growth for JANUVIA, JANUMET, GARDASIL, ISENTRESS and Strong Performance for VICTRELIS
- Reaffirmed 2012 Full-Year Non-GAAP EPS Target of $3.75 to $3.85, Excluding Certain Items; GAAP EPS Range of $2.04 to $2.30
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Apr 27, 2012 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2012.
|$ in millions, except EPS amounts||
EPS that excludes items listed below1
Net Income that excludes items listed below 1,2
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the tables that follow.
|First Quarter 2012||First Quarter 2011|
|$ in millions, except EPS amounts||
|Non-GAAP that excludes items listed below||$3,044||$0.99||$2,861||$0.92|
|Arbitration settlement charge||–||500|
|Net decrease (increase) in income before taxes||1,582||2,149|
|Estimated income tax (benefit) expense||(276)||(331)|
|Decrease (increase) in net income||$1,306||$1,818|
"We're continuing to drive double-digit growth of key brands like JANUVIA, GARDASIL and ISENTRESS, launch new products like VICTRELIS and achieve solid performance from our diverse businesses. The growth momentum of our underlying business and strength of our late-stage pipeline position us well, as we prepare for the SINGULAIR patent expiry and beyond."
Select Revenue Highlights
Worldwide sales were $11.7 billion for the first quarter of 2012, an increase of 1 percent compared with the first quarter of 2011, including a 1 percent negative effect from foreign exchange and a 2 percent unfavorable impact from the arbitration settlement agreement with Johnson & Johnson discussed below.
The following table reflects sales of the company's top pharmaceutical products, as well as total sales of animal health and consumer care products.
|PROQUAD, M-M-R II and VARIVAX||255||244||4%|
First-quarter pharmaceutical sales grew 3 percent to $10.1 billion. Adjusting pharmaceutical sales in the first quarter of 2011 to exclude sales of REMICADE (infliximab) and SIMPONI (golimumab) from the territories transferred to Johnson & Johnson as a result of the arbitration settlement agreement, pharmaceutical sales would have increased 6 percent in the first quarter of 2012.6 The revenue increases largely reflect strong sales growth for JANUVIA (sitagliptin), VICTRELIS (boceprevir), JANUMET (sitagliptin/metformin hydrochloride), GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], ZOSTAVAX (Zoster Vaccine Live) and ISENTRESS (raltegravir).
Sales from emerging markets accounted for approximately 17 percent of pharmaceutical sales in the first quarter. China grew 19 percent for the first quarter, which includes a 5 percent benefit from foreign exchange, and continues to be a key driver of growth in the emerging markets.
Worldwide sales of the combined diabetes franchise of JANUVIA/JANUMET grew 26 percent to $1.3 billion in the first quarter of 2012 driven by growth in the United States, Europe, Japan and the emerging markets.
Worldwide sales of SINGULAIR (montelukast sodium), a once-a-day oral medicine for the chronic treatment of asthma and the relief of symptoms of allergic rhinitis, grew 1 percent from the first quarter of 2011 to $1.3 billion. The U.S. patent for SINGULAIR will expire in Aug. 2012, and the company expects a significant decline in sales thereafter.
Global sales of REMICADE and SIMPONI, treatments for inflammatory diseases, declined 26 percent for the first quarter. In Europe, Russia and Turkey, where Merck retained exclusive marketing rights, the combined sales of REMICADE and SIMPONI grew 10 percent for the first quarter of 2012. In July 2011, the company transferred exclusive marketing rights for REMICADE and SIMPONI to Johnson & Johnson in Canada, Central and South America, the Middle East, Africa and Asia Pacific.
ISENTRESS, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, grew 15 percent in the first quarter driven by strong growth in the United States.
Sales recorded by Merck for GARDASIL, a vaccine to help prevent certain diseases caused by four types of human papillomavirus (HPV), were $284 million, an increase of 33 percent for the quarter driven by increased vaccination of males ages 9 through 26 and by the launch in Japan.
Sales of VICTRELIS, the company's oral hepatitis C virus NS3/4A protease inhibitor, were $111 million in the quarter, including $67 million for the United States and $44 million in the rest of the world. The company recently launched VICTRELIS in Mexico and Brazil.
Sales of ZOSTAVAX, a vaccine for the prevention of herpes zoster, were $76 million in the quarter, up from $24 million in the prior year when the company experienced supply issues. In response to the significantly improved supply status of ZOSTAVAX, the company began a U.S. national television campaign in April to help educate consumers about the risk of shingles.
As expected, global sales of Merck's antihypertensive medicines COZAAR (losartan potassium) and HYZAAR (losartan potassium and hydrochlorothiazide) continued to decline in the first quarter of 2012 following loss of marketing exclusivity in the United States and in major European markets in 2010.
Animal Health Revenue Performance
Animal Health sales totaled $821 million for the first quarter of 2012, an 8 percent increase over the first quarter of 2011, including a 2 percent negative impact due to foreign exchange. Animal Health had strong performance in the quarter across most regions, with growth led by increased sales of cattle and companion animal products. The division's products include pharmaceutical and vaccine products for the prevention, treatment and control of disease in all major farm and companion animal species.
Consumer Care Revenue Performance
First-quarter global sales of Consumer Care were $554 million, an increase of 7 percent compared to the first quarter of 2011. The sales increase was primarily due to COPPERTONE and the DR. SCHOLL'S footcare line.
Other Revenue Performance
Other revenues – primarily comprised of alliance revenue, miscellaneous corporate revenues and third-party manufacturing sales – declined 43 percent to $274 million. The change was driven largely by lower revenue from AstraZeneca LP recorded by Merck, which declined 42 percent to $186 million, as well as by lower third-party manufacturing sales partially due to the divestiture of certain manufacturing facilities in 2011.
First-Quarter Expense and Other Information
The costs detailed below totaled $9.2 billion on a GAAP basis during the first quarter of 2012 and include $1.6 billion of acquisition-related costs and restructuring costs.
|$ in millions||Included in expenses for the period|
|First Quarter 2012||
|Materials and production||$4,037||$1,229||$5||$2,803|
|Marketing and administrative||3,074||51||24||2,999|
|Research and development||1,862||9||45||1,808|
|First Quarter 2011|
|Materials and production||$4,059||$1,297||$72||$2,690|
|Marketing and administrative||3,164||58||23||3,083|
|Research and development||2,158||302||45||1,811|
Marketing and administrative expenses, on a non-GAAP basis, were $3.0 billion in the first quarter of 2012, a decrease from $3.1 billion in the first quarter of 2011. The decrease was primarily due to ongoing productivity measures.
Research and development (R&D) expenses, on a non-GAAP basis, were $1.8 billion in the first quarter of 2012, comparable with the first quarter of 2011.
Equity income from affiliates was $110 million for the first quarter, which primarily reflects the performance of partnerships with AstraZeneca LP and Sanofi Pasteur MSD.
Other (income) expense, net was $142 million of expense in the first quarter of 2012, compared to $622 million of expense in the first quarter 2011. The first quarter of 2011 included a $500 million charge related to the resolution of the arbitration proceeding with Johnson & Johnson.
The company noted the following developments:
- Obtained U.S. Food and Drug Administration (FDA) approval for JANUMET XR (sitagliptin/metformin hydrochloride extended-release) tablets. JANUMET XR is a new treatment for type 2 diabetes that combines sitagliptin with extended-release metformin in a once-daily formulation as a treatment option for patients who need help to control their blood sugar.
- Confirmed plans to file a New Drug Application with the FDA in 2012 for suvorexant, an investigational dual orexin receptor antagonist for the treatment of insomnia, based on the positive results of two pivotal Phase III studies.
- Received FDA approval for ZIOPTAN (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Announced plans for a joint venture with Supera Farma Laboratorios S.A. to commercialize innovative pharmaceutical products and branded generics in Brazil.
- Signed an agreement in April with Endocyte Inc. for rights to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide for multiple cancer indications.
Merck reiterated that it expects full-year 2012 non-GAAP EPS to be between $3.75 and $3.85. The company also expects the 2012 GAAP EPS range to be $2.04 to $2.30. The 2012 non-GAAP range excludes acquisition-related costs and costs related to restructuring programs.
Merck continues to expect full-year 2012 revenues to be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be affected unfavorably by about 2 to 3 percent.
In addition, the company continues to expect full-year 2012 non-GAAP R&D expenses to be at approximately the same level as in 2011 and the full-year 2012 non-GAAP tax rate to be in the range of 23 to 25 percent.
A reconciliation of anticipated 2012 EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table below.7
millions, except EPS amounts
|GAAP EPS||$2.04 to $2.30|
|Difference3||1.71 to 1.55|
|Non-GAAP EPS that excludes items listed below||$3.75 to $3.85|
|Acquisition-related costs4||$5,200 to $4,900|
|Restructuring costs||1,100 to 800|
|Net decrease (increase) in income before taxes||6,300 to 5,700|
|Estimated income tax (benefit) expense||(1,110) to (985)|
|Decrease (increase) in net income||$5,190 to $4,715|
As of March 31, 2012, Merck had approximately 84,000 employees worldwide.
Earnings Conference Call
Investors are invited to a live audio webcast of Merck's first-quarter earnings conference call today at 8:00 a.m. EDT by visiting Merck's Web site, www.merck.com/investors/events-and-presentations/home.html. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782. Journalists are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917. A replay of the call will be available starting at 11 a.m. EDT today for approximately one week. To listen to the replay, dial (404) 537-3406 or (855) 859-2056 and enter ID No. 56855442.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
1 Merck is providing certain 2012 and 2011 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP. For a description of the items, see Table 2a including the related footnotes, attached to this release.
2 Net income attributable to Merck & Co., Inc.
3 Represents the difference between calculated GAAP EPS and calculated non-GAAP EPS which may be different than the amount calculated by dividing the impact of the excluded items by the weighted average shares.
4 Includes expenses for the amortization of intangible assets and amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as intangible asset impairment charges. Also includes integration and other costs associated with mergers and acquisitions.
5 Represents a gain on the sale of certain manufacturing facilities and related assets reflected in other (income) expense, net.
|Pharmaceutical sales as reported||$10,082||$9,820||3%|
|Sales of REMICADE and SIMPONI in the territories transferred||–||(270)|
|Pharmaceutical sales as adjusted||$10,082||$9,550||6%|
& CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
|Costs, Expenses and Other|
|Materials and production (1)||4,037||4,059||-1%|
|Marketing and administrative (1)||3,074||3,164||-3%|
|Research and development (1)||1,862||2,158||-14%|
|Restructuring costs (2)||219||(14||)||*|
|Equity income from affiliates (3)||(110||)||(138||)||-20%|
|Other (income) expense, net (1) / (4)||142||622||-77%|
|Income Before Taxes||2,507||1,729||45%|
|Income Tax Provision||740||658|
|Less: Net Income Attributable to Noncontrolling Interests||29||28|
Posted: April 2012